UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 84

Sortiert nach

Novel somatic mutations in UBA1 as a cause of VEXAS syndrome

Blood, 2021-07, Vol.137 (26), p.3676-3681

2021

Volltextzugriff (PDF)

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Journal of clinical oncology, 2013-07, Vol.31 (20), p.2540-2547

2013

Volltextzugriff (PDF)

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Blood, 2015-03, Vol.125 (12), p.1932-1935

2015

Volltextzugriff (PDF)

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis

Blood, 2014-08, Vol.124 (8), p.1296-1299

2014

Volltextzugriff (PDF)

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

Haematologica (Roma), 2016-02, Vol.101 (2), p.e69

2016

Volltextzugriff (PDF)

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Journal of clinical oncology, 2022-09, Vol.40 (25), p.2889-2900

2022

Volltextzugriff (PDF)

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

Journal of clinical oncology, 2023-08, Vol.41 (23), p.3945-3955

2023

Volltextzugriff (PDF)

Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

The New England journal of medicine, 2008-08, Vol.359 (6), p.575-583

2008

Volltextzugriff (PDF)

Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial

Bone marrow transplantation (Basingstoke), 2024-03, Vol.59 (3), p.431-434

2024

Volltextzugriff (PDF)

Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort

BMJ open, 2021-02, Vol.11 (2), p.e041296-e041296

2021

Volltextzugriff (PDF)

Immunoglobulin M Concentration in Waldenström Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma Cells

Clinical lymphoma, myeloma and leukemia, 2013-04, Vol.13 (2), p.211-213

2013

Volltextzugriff (PDF)

Reply to M. Roschewski et al

Journal of clinical oncology, 2014-02, Vol.32 (5), p.476-477

2014

Volltextzugriff (PDF)

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

Blood, 2022-11, Vol.140 (Supplement 1), p.7032-7033

2022

Volltextzugriff (PDF)

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

The New England journal of medicine, 2024-01, Vol.390 (4), p.326-337

2024

Volltextzugriff (PDF)

Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia

Leukemia, 2024-04, Vol.38 (4), p.822-828

2024

Volltextzugriff (PDF)

Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK’s Haematological Malignancy Research Network

Cancer epidemiology, 2024-02, Vol.88, p.102513-102513, Article 102513

2024

Volltextzugriff (PDF)

Epigenetic control of the protocadherin-gamma locus provides a potential source of cell surface codes in B cell differentiation

The Journal of immunology (1950), 2020-05, Vol.204 (1_Supplement), p.153-153.17

2020

Volltextzugriff (PDF)

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

Blood, 2022-11, Vol.140 (Supplement 1), p.1371-1372

2022

Volltextzugriff (PDF)

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Blood, 2022-11, Vol.140 (Supplement 1), p.12626-12627

2022

Volltextzugriff (PDF)

Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Blood, 2022-11, Vol.140 (Supplement 1), p.3624-3626

2022

Volltextzugriff (PDF)

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Blood, 2021-11, Vol.138 (Supplement 1), p.820-820

2021

Volltextzugriff (PDF)

Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8001-8001

2021

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library Full Collection 2018

Zeitschrift / SeriePlos Medicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(83)

Publikationsform

Artikel
(82)
Buchkapitel
(2)

Sprache

Englisch
(84)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Hematology
(15)
Oncology
(12)
Female
(10)
Male
(9)
Aged
(7)
Middle Aged
(7)
Multiple Myeloma - Drug Therapy
(7)
Myeloma
(7)
Transplantation, Autologous
(5)
Adult
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Flow Cytometry
(4)
General & Internal Medicine
(4)
Medicine, General & Internal
(4)
Multiple Myeloma
(4)
Multiple Myeloma - Diagnosis
(4)
Treatment Outcome
(4)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

8 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Novel somatic mutations in UBA1 as a cause of VEXAS syndrome

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial

Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial

Immunoglobulin M Concentration in Waldenström Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma Cells

Reply to M. Roschewski et al

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia

Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK’s Haematological Malignancy Research Network

Epigenetic control of the protocadherin-gamma locus provides a potential source of cell surface codes in B cell differentiation

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial

Aktive Filter

Suchergebnisse filtern